Vibrio cholerae O139 capsular polysaccharide confers complement resistance in the absence or presence of antibody yet presents a productive target for cell lysis: implications for detection of bactericidal antibodies

Microbial Pathogenesis

Volumn 47, Issue 6, 2009, Pages 314-320

  Attridge, Stephen R ^a   Holmgren, Jan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bacteriolysis; Capsule; Complement; LPS; V. cholerae O139

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; CAPSULAR POLYSACCHARIDE; CHOLERA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOLYSIS; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; STRAIN DIFFERENCE; VIBRIO CHOLERAE;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; BACTERIOLYSIS; CHOLERA; CHOLERA VACCINES; COMPLEMENT SYSTEM PROTEINS; GUINEA PIGS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MUTATION; RABBITS; SERUM BACTERICIDAL TEST; VIBRIO CHOLERAE O139;

MUS; VIBRIO CHOLERAE;

EID: 71449125246     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2009.09.013     Document Type: Article

References (25)

1. Faruque S.M., Chowdhury N., Kamruzzaman M., Ahmad Q.S., Faruque A.S.G., Salam M.A., et al. Reemergence of epidemic Vibrio cholerae O139, Bangladesh. Emerging Inf Dis 9 (2003) 1116-1122
2. Sinha S.R., Chakraborty R., De K., Khan A., Datta S., Ramamurty T., et al. Escalating association of Vibrio cholerae O139 with cholera outbreaks in India. J Clin Microbiol 40 (2002) 2635-2637
3. World Health Organization. Cholera, 2004. Weekly epidemiological record 2005; 80: 261-68.
4. Trach D.D., Cam P.D., Ke N.T., Rao M.R., Dinh D., Hang P.V., et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull WHO 80 (2002) 2-8
5. Anh D.D., Canh D.G., Lopez A.L., Thiem V.D., Long P.T., Son N.H., et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25 (2007) 1149-1155
6. Levine M.M., and Tacket C.O. Recombinant live cholera vaccines. In: Wachsmuth I.K., Blake P.A., and Olsvik O. (Eds). Vibrio cholerae and cholera. Molecular to global perspectives (1994), ASM Press, Washington DC 395-413
7. Morris Jr. J.G., Losonsky G.A., Johnson J.A., Tacket C.O., Nataro J.P., Panigrahi P., et al. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J Infect Dis 171 (1995) 903-908
8. Tacket C.O., Losonsky G., Nataro J.P., Comstock L., Michalski J., Edelman R., et al. Initial clinical studies of CVD112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis 172 (1995) 883-886
9. Coster T.S., Killeen K.P., Waldor M.K., Beattie D.T., Spriggs D.R., Kenner J.R., et al. Safety, immunogenicity and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 345 (1995) 949-952
10. Jertborn M., Svennerholm A.-M., and Holmgren J. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine. Vaccine 15 (1996) 1459-1465
11. Saha D., LaRocque R.C., Khan A.I., Harris J.B., Begum Y.A., Akramuzzaman S.M., et al. Incomplete correlation of serum vibriocidal antibody titre with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis 189 (2004) 2318-2322
12. Attridge S.R., Qadri F., Albert M.J., and Manning P.A. Susceptibility of Vibrio cholerae O139 to antibody-dependent, complement-mediated bacteriolysis. Clin Diag Lab Immunol 7 (2000) 444-450
13. Qadri F., Svennerholm A.-M., Shamsuzzaman S., Bhuiyan T.R., Harris J.B., Ghosh A.N., et al. Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh. Infect Immun 73 (2005) 6577-6583
14. Attridge S.R., Fazeli A., Manning P.A., and Stroeher U. Isolation and characterization of bacteriophage-resistant mutants of Vibrio cholerae O139. Microb Pathog 30 (2001) 237-246
15. Attridge S.R., Wallerström G., Li B.-L., Morona R., and Holmgren J. Differential immunogenicity of Vibrio cholerae O139 variants expressing different combinations of naturally occurring and atypical forms of the serogroup polysaccharide. Vaccine 27 (2009) 1055-1061
16. Waldor M.K., Colwell R., and Mekalanos J.J. The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants. PNAS 91 (1994) 11388-11392
17. Nesper J., Schild S., Lauriano C.L., Kraiss A., Klose K.E., and Reidl J. Role of Vibrio cholerae O139 surface polysaccharides in intestinal colonization. Infect Immun 70 (2002) 5990-5996
18. Attridge S.R., Johansson C., Trach D.D., Qadri F., and Svennerholm A.-M. A sensitive microplate assay for the detection of bactericidal antibodies to Vibrio cholerae O139. Clin Diag Lab Immunol 9 (2002) 383-387
19. Favre D., Cryz Jr. S.J., and Viret J.-F. Construction and characterization of a potential live oral carrier-based vaccine against Vibrio cholerae O139. Infect Immun 64 (1996) 3565-3570
20. Kossaczka Z., Shiloach J., Johnson V., Taylor D.N., Finkelstein R.A., Robbins J.B., et al. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin in mice. Infect Immun 68 (2000) 5037-5043
21. Scheerson R., Rodrigues L.P., Clarke Jr. J.C., and Robbins J.B. Immunity to disease caused by Hemophilus influenzae Type b. II. Specificity and some biological characteristics of 'natural', infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae Type b. J Immunol 107 (1971) 1081-1089
22. Rubinstein L.J., and Stein K.E. Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. J Immunol 141 (1988) 4357-4362
23. Losonsky G.A., Lim Y., Motamedi P., Comstock L.E., Johnson J.A., Morris Jr. J.G., et al. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity. Clin Diag Lag Immunol 4 (1997) 264-269
24. Manning P.A., Stroeher U.H., and Morona R. Molecular basis for O-antigen biosynthesis in Vibrio cholerae O1: Ogawa-Inaba switching. In: Wachsmuth I.K., Blake P.A., and Olsvik O. (Eds). Vibrio cholerae and cholera. Molecular to global perspectives (1994), ASM Press, Washington DC 77-94
25. Mahalanabis D., Lopez A.L., Sur D., Deen J., Manna B., Kanungo S., et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS ONE 3 (2008) e2323